Corient Private Wealth
AXSM icon

Corient Private Wealth’s Axsome Therapeutics AXSM Stock Holding History

Corient Private Wealth’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$868K Buy
+5,143
New +$888K ﹤0.01% 1736
2025
Q1 		– Sell
-2,829
Closed -$239K – 2293
2024
Q4 		$239K Buy
+2,829
New +$260K ﹤0.01% 2017

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corient Private Wealth's AXSM Position: Q1 2026 in Review

Corient Private Wealth opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 5,143 shares worth $868K. The stake represents ﹤0.01% of the portfolio and ranks #1736 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in AXSM as recently as Q4 2024.

Corient Private Wealth first reported a position in AXSM in Q4 2024 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Corient Private Wealth held 5,143 shares of Axsome Therapeutics worth $868K as of Q1 2026.
  • Axsome Therapeutics was a new Corient Private Wealth position in Q1 2026.
  • Axsome Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1736 holding.
  • Corient Private Wealth first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.